Two-year outcome of vagus nerve stimulation in treatment-resistant depression

Malek Bajbouj, Angela Merkl, Thomas E. Schlaepfer, Caroline Frick, Astrid Zobel, Wolfgang Maier, Veronica O'Keane, Ciaran Corcoran, Rolf Adolfsson, Michael Trimble, Harald Rau, Hans Joachim Hoff, Frank Padberg, Florian Müller-Siecheneder, Kurt Audenaert, Dirk Van Den Abbeele, Keith Matthews, David Christmas, Sam Eljamel, Isabella Heuser

Research output: Contribution to journalArticle

Abstract

One of the major goals of antidepressant treatment is a sustained response and remission of depressive symptoms. Some of the previous studies of vagus nerve stimulation (VNS) have suggested antidepressant effects. Our naturalistic study assessed the efficacy and the safety of VNS in 74 European patients with therapy-resistant major depressive disorder. Psychometric measures were obtained after 3, 12, and 24 months of VNS. Mixed-model repeated-measures analysis of variance revealed a significant reduction (P ≤ 0.05) at all the 3 time points in the 28-item Hamilton Rating Scale for Depression (HRSD28) score, the primary outcome measure. After 2 years, 53.1% (26/49) of the patients fulfilled the response criteria (≥50% reduction in the HRSD28 scores from baseline) and 38.9% (19/49) fulfilled the remission criteria (HRSD28 scores ≤ 10). The proportion of patients who fulfilled the remission criteria remained constant as the duration of VNS treatment increased. Voice alteration, cough, and pain were the most frequently reported adverse effects. Two patients committed suicide during the study; no other deaths were reported. No statistically significant differences were seen in the number of concomitant antidepressant medications. The results of this 2-year open-label trial suggest a clinical response and a comparatively benign adverse effect profile among patients with treatment-resistant depression.

Original languageEnglish (US)
Pages (from-to)273-281
Number of pages9
JournalJournal of Clinical Psychopharmacology
Volume30
Issue number3
DOIs
StatePublished - Jun 2010

Fingerprint

Treatment-Resistant Depressive Disorder
Vagus Nerve Stimulation
Antidepressive Agents
Depression
Major Depressive Disorder
Cough
Psychometrics
Suicide
Analysis of Variance
Therapeutics
Outcome Assessment (Health Care)
Safety
Pain

Keywords

  • Clinical trial
  • Depression
  • Hamilton Rating Scale for Depression
  • Major depressive disorder
  • Vagus nerve stimulation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Two-year outcome of vagus nerve stimulation in treatment-resistant depression. / Bajbouj, Malek; Merkl, Angela; Schlaepfer, Thomas E.; Frick, Caroline; Zobel, Astrid; Maier, Wolfgang; O'Keane, Veronica; Corcoran, Ciaran; Adolfsson, Rolf; Trimble, Michael; Rau, Harald; Hoff, Hans Joachim; Padberg, Frank; Müller-Siecheneder, Florian; Audenaert, Kurt; Van Den Abbeele, Dirk; Matthews, Keith; Christmas, David; Eljamel, Sam; Heuser, Isabella.

In: Journal of Clinical Psychopharmacology, Vol. 30, No. 3, 06.2010, p. 273-281.

Research output: Contribution to journalArticle

Bajbouj, M, Merkl, A, Schlaepfer, TE, Frick, C, Zobel, A, Maier, W, O'Keane, V, Corcoran, C, Adolfsson, R, Trimble, M, Rau, H, Hoff, HJ, Padberg, F, Müller-Siecheneder, F, Audenaert, K, Van Den Abbeele, D, Matthews, K, Christmas, D, Eljamel, S & Heuser, I 2010, 'Two-year outcome of vagus nerve stimulation in treatment-resistant depression', Journal of Clinical Psychopharmacology, vol. 30, no. 3, pp. 273-281. https://doi.org/10.1097/JCP.0b013e3181db8831
Bajbouj, Malek ; Merkl, Angela ; Schlaepfer, Thomas E. ; Frick, Caroline ; Zobel, Astrid ; Maier, Wolfgang ; O'Keane, Veronica ; Corcoran, Ciaran ; Adolfsson, Rolf ; Trimble, Michael ; Rau, Harald ; Hoff, Hans Joachim ; Padberg, Frank ; Müller-Siecheneder, Florian ; Audenaert, Kurt ; Van Den Abbeele, Dirk ; Matthews, Keith ; Christmas, David ; Eljamel, Sam ; Heuser, Isabella. / Two-year outcome of vagus nerve stimulation in treatment-resistant depression. In: Journal of Clinical Psychopharmacology. 2010 ; Vol. 30, No. 3. pp. 273-281.
@article{686a446bdba848e1b88864c75db1871c,
title = "Two-year outcome of vagus nerve stimulation in treatment-resistant depression",
abstract = "One of the major goals of antidepressant treatment is a sustained response and remission of depressive symptoms. Some of the previous studies of vagus nerve stimulation (VNS) have suggested antidepressant effects. Our naturalistic study assessed the efficacy and the safety of VNS in 74 European patients with therapy-resistant major depressive disorder. Psychometric measures were obtained after 3, 12, and 24 months of VNS. Mixed-model repeated-measures analysis of variance revealed a significant reduction (P ≤ 0.05) at all the 3 time points in the 28-item Hamilton Rating Scale for Depression (HRSD28) score, the primary outcome measure. After 2 years, 53.1{\%} (26/49) of the patients fulfilled the response criteria (≥50{\%} reduction in the HRSD28 scores from baseline) and 38.9{\%} (19/49) fulfilled the remission criteria (HRSD28 scores ≤ 10). The proportion of patients who fulfilled the remission criteria remained constant as the duration of VNS treatment increased. Voice alteration, cough, and pain were the most frequently reported adverse effects. Two patients committed suicide during the study; no other deaths were reported. No statistically significant differences were seen in the number of concomitant antidepressant medications. The results of this 2-year open-label trial suggest a clinical response and a comparatively benign adverse effect profile among patients with treatment-resistant depression.",
keywords = "Clinical trial, Depression, Hamilton Rating Scale for Depression, Major depressive disorder, Vagus nerve stimulation",
author = "Malek Bajbouj and Angela Merkl and Schlaepfer, {Thomas E.} and Caroline Frick and Astrid Zobel and Wolfgang Maier and Veronica O'Keane and Ciaran Corcoran and Rolf Adolfsson and Michael Trimble and Harald Rau and Hoff, {Hans Joachim} and Frank Padberg and Florian M{\"u}ller-Siecheneder and Kurt Audenaert and {Van Den Abbeele}, Dirk and Keith Matthews and David Christmas and Sam Eljamel and Isabella Heuser",
year = "2010",
month = "6",
doi = "10.1097/JCP.0b013e3181db8831",
language = "English (US)",
volume = "30",
pages = "273--281",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Two-year outcome of vagus nerve stimulation in treatment-resistant depression

AU - Bajbouj, Malek

AU - Merkl, Angela

AU - Schlaepfer, Thomas E.

AU - Frick, Caroline

AU - Zobel, Astrid

AU - Maier, Wolfgang

AU - O'Keane, Veronica

AU - Corcoran, Ciaran

AU - Adolfsson, Rolf

AU - Trimble, Michael

AU - Rau, Harald

AU - Hoff, Hans Joachim

AU - Padberg, Frank

AU - Müller-Siecheneder, Florian

AU - Audenaert, Kurt

AU - Van Den Abbeele, Dirk

AU - Matthews, Keith

AU - Christmas, David

AU - Eljamel, Sam

AU - Heuser, Isabella

PY - 2010/6

Y1 - 2010/6

N2 - One of the major goals of antidepressant treatment is a sustained response and remission of depressive symptoms. Some of the previous studies of vagus nerve stimulation (VNS) have suggested antidepressant effects. Our naturalistic study assessed the efficacy and the safety of VNS in 74 European patients with therapy-resistant major depressive disorder. Psychometric measures were obtained after 3, 12, and 24 months of VNS. Mixed-model repeated-measures analysis of variance revealed a significant reduction (P ≤ 0.05) at all the 3 time points in the 28-item Hamilton Rating Scale for Depression (HRSD28) score, the primary outcome measure. After 2 years, 53.1% (26/49) of the patients fulfilled the response criteria (≥50% reduction in the HRSD28 scores from baseline) and 38.9% (19/49) fulfilled the remission criteria (HRSD28 scores ≤ 10). The proportion of patients who fulfilled the remission criteria remained constant as the duration of VNS treatment increased. Voice alteration, cough, and pain were the most frequently reported adverse effects. Two patients committed suicide during the study; no other deaths were reported. No statistically significant differences were seen in the number of concomitant antidepressant medications. The results of this 2-year open-label trial suggest a clinical response and a comparatively benign adverse effect profile among patients with treatment-resistant depression.

AB - One of the major goals of antidepressant treatment is a sustained response and remission of depressive symptoms. Some of the previous studies of vagus nerve stimulation (VNS) have suggested antidepressant effects. Our naturalistic study assessed the efficacy and the safety of VNS in 74 European patients with therapy-resistant major depressive disorder. Psychometric measures were obtained after 3, 12, and 24 months of VNS. Mixed-model repeated-measures analysis of variance revealed a significant reduction (P ≤ 0.05) at all the 3 time points in the 28-item Hamilton Rating Scale for Depression (HRSD28) score, the primary outcome measure. After 2 years, 53.1% (26/49) of the patients fulfilled the response criteria (≥50% reduction in the HRSD28 scores from baseline) and 38.9% (19/49) fulfilled the remission criteria (HRSD28 scores ≤ 10). The proportion of patients who fulfilled the remission criteria remained constant as the duration of VNS treatment increased. Voice alteration, cough, and pain were the most frequently reported adverse effects. Two patients committed suicide during the study; no other deaths were reported. No statistically significant differences were seen in the number of concomitant antidepressant medications. The results of this 2-year open-label trial suggest a clinical response and a comparatively benign adverse effect profile among patients with treatment-resistant depression.

KW - Clinical trial

KW - Depression

KW - Hamilton Rating Scale for Depression

KW - Major depressive disorder

KW - Vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=77952330742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952330742&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181db8831

DO - 10.1097/JCP.0b013e3181db8831

M3 - Article

VL - 30

SP - 273

EP - 281

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -